Published in

American Medical Association, Journal of the American Medical Association, 9(293), p. 1073

DOI: 10.1001/jama.293.9.1073

Taylor & Francis, Women's Oncology Review, 2(5), p. 109-111

DOI: 10.1080/14733400500178618

Taylor & Francis, Women's Oncology Review, 2(5), p. 109-111

DOI: 10.3109/14733400500178618

Links

Tools

Export citation

Search in Google Scholar

Adjuvant chemotherapy in older and younger women with lymph node–positive breast cancer

Journal article published in 2005 by Susan Woolf, Daniel Weiss, Md I. Wood, Eric Winer, Judith Wheeler, Larry Norton, Christopher Steer ORCID, Sumitra Ananda, Bs Donald Berry, Constance Cirrincione, Raymond B. Ms, William C. Budman, Craig Henderson, Clifford Hudis, Hyman B. Muss and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

cer increases with increasing age, and almost half of all new breast cancers in the United States now occur in women 65 years of age or older. 1 Systemic adjuvant che-motherapy in women with early-stage breast cancer significantly improves both relapse-free and overall survival for women aged 50 to 69 years old, but data are lacking for women aged 70 years or older. 2 Nevertheless, avail-able data suggest that systemic adju-vant chemotherapy may be signifi-cantly underused in older patients, 3 even though for many patients in this setting, chemotherapy may improve survival. Moreover, even when chemo-For editorial comment see p 1118.